16.20
Mediwound Ltd stock is traded at $16.20, with a volume of 103.45K.
It is up +0.56% in the last 24 hours and down -6.36% over the past month.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
See More
Previous Close:
$16.11
Open:
$16.33
24h Volume:
103.45K
Relative Volume:
1.06
Market Cap:
$208.10M
Revenue:
$16.96M
Net Income/Loss:
$-23.88M
P/E Ratio:
-7.7253
EPS:
-2.097
Net Cash Flow:
$-20.66M
1W Performance:
-4.59%
1M Performance:
-6.36%
6M Performance:
-7.38%
1Y Performance:
+0.81%
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
MDWD
Mediwound Ltd
|
16.20 | 206.94M | 16.96M | -23.88M | -20.66M | -2.097 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
INSM
Insmed Inc
|
165.01 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-02-25 | Initiated | Alliance Global Partners | Buy |
| Feb-28-25 | Initiated | Craig Hallum | Buy |
| Jul-16-24 | Reiterated | Maxim Group | Buy |
| Dec-22-22 | Initiated | Maxim Group | Buy |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
| Sep-23-20 | Initiated | BTIG Research | Buy |
| Nov-28-16 | Initiated | Aegis Capital | Buy |
| Aug-17-16 | Initiated | Wells Fargo | Outperform |
| Apr-16-14 | Initiated | Oppenheimer | Outperform |
View All
Mediwound Ltd Stock (MDWD) Latest News
Avoiding Lag: Real-Time Signals in (MDWD) Movement - Stock Traders Daily
MediWound Sets May 6, 2026 Shareholder Meeting to Vote on Board, Auditor and CEO Bonus - TipRanks
MediWound (NASDAQ: MDWD) plans 2026 AGM, director slate and CEO bonus - Stock Titan
Fed Meeting: Should value investors consider MediWound LtdSell Signal & Daily Profit Focused Stock Screening - baoquankhu1.vn
MediWound (MDWD) director details options, RSU and share holdings - Stock Titan
MediWound Ltd. (NASDAQ:MDWD) Q4 2025 earnings call transcript - msn.com
Gap Down: Can MediWound Ltd keep up with sector leaders2026 Sector Review & Smart Swing Trading Alerts - baoquankhu1.vn
Pullback Watch: Does MediWound Ltd meet Warren Buffetts criteriaEarnings Overview Report & Weekly Consistent Profit Watchlists - baoquankhu1.vn
MediWound (NASDAQ:MDWD) Stock Passes Below 200-Day Moving AverageTime to Sell? - MarketBeat
Discipline and Rules-Based Execution in MDWD Response - Stock Traders Daily
Aug Drivers: Will MediWound Ltd outperform the market in YEARGap Down & Verified Short-Term Plans - baoquankhu1.vn
MediWound (MDWD) director Rubinstein reports options and share holdings - Stock Titan
[Form 3] MediWound Ltd. Initial Stateme... - Stock Titan
MediWound (MDWD) CMO details options and RSU awards in Form 3 filing - Stock Titan
MediWound Ltd. (MDWD) director discloses shares, RSUs and options stake - Stock Titan
MediWound (MDWD) VP reports stock options and RSU holdings in Form 3 - Stock Titan
MediWound (MDWD) EVP Meyer Yaron files Form 3 on equity holdings - Stock Titan
MediWound (MDWD) details director Stephen Wills’ initial share and option holdings - Stock Titan
MediWound (MDWD) COO Shmuel details option and RSU holdings in Form 3 - Stock Titan
MediWound (MDWD) CEO details warrants, RSUs and options in Form 3 - Stock Titan
MediWound (MDWD) director Nachum Shamir details shares, RSUs and options - Stock Titan
MediWound (MDWD) Stock Price, News & Analysis - MarketBeat
Medical Maggots Market Hits New High | Major Giants BioMonde, Maggot Therapy, MediWound - openPR.com
Menora Mivtachim Holdings LTD. Purchases 61,039 Shares of MediWound Ltd. $MDWD - MarketBeat
Rosalind Advisors Inc. Buys 341,993 Shares of MediWound Ltd. $MDWD - MarketBeat
Performance Recap: Is MediWound Ltd forming a bullish divergenceDip Buying & AI Optimized Trading Strategy Guides - baoquankhu1.vn
FY2030 Earnings Estimate for MediWound Issued By Maxim Group - Defense World
Institution Moves: Does MediWound Ltd meet Warren Buffetts criteria2026 Earnings Impact & Advanced Swing Trade Entry Plans - baoquankhu1.vn
FY2030 Earnings Forecast for MediWound Issued By Maxim Group - MarketBeat
MediWound Is the Biotech Governments Have Been Stockpiling for E - GuruFocus
MediWound Is the Biotech Governments Have Been Stockpiling for Exactly These Kinds of Wars (NASDAQ: MDWD) - TipRanks
MediWound outlines $24M–$26M 2026 revenue target while expanding EscharEx clinical programs - MSN
MediWound (MDWD) Q4 2025 Earnings Call Transcript - AOL.com
MDWD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MediWound Ltd. (NASDAQ:MDWD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Behavioral Patterns of MDWD and Institutional Flows - Stock Traders Daily
MediWound (NASDAQ:MDWD) Stock Rating Lowered by Wall Street Zen - MarketBeat
MediWound Ltd. (NASDAQ:MDWD) Q4 2025 Earnings Call Transcript - Insider Monkey
MediWound: Q4 Earnings Snapshot - theheraldreview.com
Mediwound earnings beat by $0.03, revenue fell short of estimates - Investing.com Australia
MediWound Q4 Earnings Call Highlights - MarketBeat
MediWound (MDWD) Heavy FY 2025 Losses Test High Growth And Premium P/S Narrative - simplywall.st
MediWound Q4 2025 Earnings Call Transcript - MarketBeat
MediWound Files Annual Report on Form 20-F - Bluefield Daily Telegraph
MediWound Ltd. Q4 2025 Earnings Call Summary - Yahoo Finance
MediWound (NASDAQ:MDWD) Issues Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
MDWD: Expanded manufacturing, clinical progress, and strong guidance despite 2025 revenue decline - TradingView
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
MediWound (MDWD) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
MDWD Maintains Revenue Forecasts Through 2028 - GuruFocus
MediWound (MDWD) Reports Lower-than-Expected Q4 Revenue - GuruFocus
Mediwound Ltd Stock (MDWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):